Pharma Globenewswire

Quetzal Therapeutics’ QTX-2101 Secures FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

3 February 2026

Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, today announced that the Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, the company’s investigational oral arsenic trioxide capsule, for the treatment of patients with acute

Uncategorised

Antisense Oligonucleotide Therapeutics Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

2 February 2026

DelveInsight’s, “Antisense Oligonucleotide Therapeutics Pipeline Insights 2025” report provides comprehensive insights about 70+ companies and 90+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It also covers

Uncategorised

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

2 February 2026

DelveInsight’s, “Untreated Metastatic or Unresectable Melanoma Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Untreated Metastatic or Unresectable Melanoma pipeline landscape. It covers the Untreated Metastatic or Unresectable Melanoma pipeline drug profiles, including clinical and

Uncategorised

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus: A First-in-Class BDCA2 Targeting Therapy

2 February 2026

The Food and Drug Administration (FDA) has granted breakthrough therapy designation to litifilimab (BIIB059), a humanized monoclonal antibody developed by Biogen, for the treatment of cutaneous lupus erythematosus (CLE). This regulatory milestone represents a significant advancement for patients living with an orphan

Clinical Trials

FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation for First-Line Treatment of Elderly Patients with Acute Myeloid Leukemia

2 February 2026

The Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to IPN60340 (ICT01), Ipsen’s investigational anti-BTN3A monoclonal antibody, in combination with venetoclax and azacitidine for first-line treatment of acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy. This regulatory acceleration

Uncategorised

Pneumococcal Infections Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

29 January 2026

DelveInsight’s, “Pneumococcal Infections Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pneumococcal Infections pipeline landscape. It covers the Pneumococcal Infections pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pneumococcal Infections

Uncategorised

Non-Cystic Fibrosis Bronchiectasis Market Size is projected to grow at a CAGR of 16.25% by 2034, estimates DelveInsight

29 January 2026

DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of Non-Cystic Fibrosis Bronchiectasis (NCFB), including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom),

Uncategorised

Bioanalytical Testing Services Market Size Expected to Witness Significant Expansion at ~16% CAGR by 2032 | DelveInsight

29 January 2026

DelveInsight’s Bioanalytical Testing Services Market Insights Report 2032 provides the current and forecast market analysis, individual leading Bioanalytical Testing Services Companies market shares, challenges, Bioanalytical Testing Services Market Drivers, barriers, trends, and key market Bioanalytical Testing Services companies in the market. Get

Uncategorised

Big Data in Healthcare Market Size is estimated to grow at a CAGR of 20.11%, estimates DelveInsight

29 January 2026

DelveInsight’s Big Data in Healthcare Market Insights Report 2032 provides the current and forecast market analysis, individual leading Big Data in Healthcare Companies market shares, challenges, Big Data in Healthcare Market Drivers, barriers, trends, and key market Big Data in Healthcare companies

Latest

Quetzal Therapeutics’ QTX-2101 Secures FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

Antisense Oligonucleotide Therapeutics Treatment Pipeline Shows Strong Momentum as 70+ Pharma Companies in the Race | DelveInsight

Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in the Therapeutics | DelveInsight

Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus: A First-in-Class BDCA2 Targeting Therapy

FDA Grants Ipsen’s IPN60340 Breakthrough Therapy Designation for First-Line Treatment of Elderly Patients with Acute Myeloid Leukemia

Pneumococcal Infections Clinical Trial Pipeline Expands as 15+ Companies Driving Innovation in the Therapeutics | DelveInsight

Non-Cystic Fibrosis Bronchiectasis Market Size is projected to grow at a CAGR of 16.25% by 2034, estimates DelveInsight

Bioanalytical Testing Services Market Size Expected to Witness Significant Expansion at ~16% CAGR by 2032 | DelveInsight

Big Data in Healthcare Market Size is estimated to grow at a CAGR of 20.11%, estimates DelveInsight

Recent Posts

Banner

Newsletter

Authors